CordenPharma Driving innovation and leadership: CordenPharma shortlisted for two CPHI Pharma Awards environmentally burdensome, and limited in worldwide production capacity. TAPS solves this by combining the control of SPPS with the scalability of LPPS, eliminating resin use, reducing solvent consumption by over 90% and substantially reducing the amount of raw materials used. The peptide remains in the organic phase via a patented TAG-anchor molecule while impurities and excess amino-acid derivatives or reagents are extracted into the aqueous phase. CordenPharma is very proud to be shortlisted as a finalist in two categories at the CPHI Awards 2025! The CPHI Pharma Awards celebrate the forefront of innovation, excellence, and collaboration in the pharmaceutical industry. These prestigious awards honor pioneers driving advancements in drug development, revolutionizing manufacturing processes, championing sustainability, and shaping the future of pharma worldwide. Against this backdrop, CordenPharma is proud to be shortlisted as a finalist in two categories at the CPHI Awards 2025 - API Development & Innovation and CEO of the Year - which recognize both our innovative technology and leadership in combining deep scientific expertise with a commitment to improving patient outcomes. We are shortlisted for our Tag-Assisted Peptide Synthesis (TAPS), a next-generation technology revolutionizing peptide manufacturing to meet the growing demand for scalable and sustainable peptide outsourcing. Indeed, the global peptide therapeutics market is expanding rapidly, driven by biologically active peptides like GLP-1 analogues. However, current manufacturing technologies, particularly SPPS, are resource-intensive, API development and innovation 14CPHI FRANKFURT 2025 PREVIEW
RkJQdWJsaXNoZXIy MjY2OTA4MA==